読み込み中
NASDAQHealthcareBiotechnology
最新データ
$30.65
+$0.80 · +2.68%
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
終値時点
$30.65
+$0.80 · +2.68%
時間外
$30.65
$0.00 · 0.00%
10月9日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
日中レンジ
現在 $30.65
52週レンジ
現在 $30.65
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
38
割高
センチメント
63
強気
リスク
41
やや高いリスク
モメンタム
74
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
日中レンジ
現在 $30.65
52週レンジ
現在 $30.65
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|
| 売上原価 | — | — | — | 1.5万 USD |
| 粗利益 | — | — | — | −1.5万 USD |
| 研究開発 | 9478.9万 USD | 6093.5万 USD | 2799.9万 USD | 911.5万 USD |
| 販売・一般管理 | 3031万 USD | 2212万 USD | 818万 USD | 136.58万 USD |
| 営業費用 | 1.25億 USD | 8305.5万 USD | 3617.9万 USD | 1035.2万 USD |
| 受取利息 | 1361.6万 USD | 1213.8万 USD | 252.7万 USD | — |
| 支払利息 | — | — | — | 28.5万 USD |
| 減価償却費と償却費 | 101.7万 USD | 83.9万 USD | 11.2万 USD | 1.5万 USD |
| 営業利益 | −1.25億 USD | −8305.5万 USD | −3617.9万 USD | −1036.7万 USD |
| 純利益 | −1.11億 USD | −7830.7万 USD | −3478.6万 USD | −1065.2万 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$67.00
上昇余地（118.60%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI4802.41万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM2409.27万0.03%781.81億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF1619.79万0.02%954億 USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO857.17万0.05%180億 USD0.06%$112.66+0.50%
iShares Russell 2000 Growth ETFIWO790.35万0.06%140.44億 USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB664.58万0.06%102.68億 USD0.44%$206.49+3.00%
Dimensional - US Small Cap ETFDFAS602.22万0.02%337.96億 USD0.31%$78.35+0.32%
State Street SPDR S&P Pharmaceuticals ETFXPH582.16万1.28%4.53億 USD0.35%$64.65+1.60%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASState Street SPDR S&P Pharmaceuticals ETFXPHAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
